AJ
ALXN

Ashburton (Jersey)’s Alexion Pharmaceuticals ALXN Stock Holding History

Ashburton (Jersey)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-12,029
Closed -$1.41M – 83
2016
Q2 		$1.41M Sell
12,029
-4,096
-25% -$581K 0.58% 47
2016
Q1 		$2.25M Sell
16,125
-2,980
-16% -$438K 0.79% 35
2015
Q4 		$3.65M Buy
+19,105
New +$3.34M 0.97% 31

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Ashburton (Jersey)'s ALXN Position: Q3 2016 in Review

Ashburton (Jersey) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 12,029 shares — an estimated $1.41M sold.

Ashburton (Jersey) first reported a position in ALXN in Q4 2015 and held it in 3 quarters. The position peaked at $3.65M in Q4 2015. 519 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Ashburton (Jersey) reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Ashburton (Jersey) sold 12,029 Alexion Pharmaceuticals shares in Q3 2016, an estimated $1.41M.
  • Ashburton (Jersey) first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Ashburton (Jersey)'s Alexion Pharmaceuticals position peaked at $3.65M in Q4 2015.
  • 519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Ashburton (Jersey)'s 13F filing for Q3 2016, filed 25 Nov 2016.